I read with interest the advertisement for “FDA-Approved Acthar” (repository corticotropin injection) for symptomatic sarcoidosis in the October issue of CHEST. Acthar is being marketed by Mallinckrodt Pharmaceuticals to pulmonologists for the treatment of sarcoidosis. The U.S. Food and Drug Administration approval for this drug was obtained decades ago, when the only requirement for approval was that a drug be proven to be safe. I was surprised to see this advertisement because there is no physiological reason to believe that injectable corticotropin is any safer or more effective than oral corticosteroids. While the advertisement lists all of the precautions and complications that would be expected for corticosteroid therapy, no studies in support of its use are provided, nor could I find any such data from any clinical trials at either PubMed or Clinicaltrials.gov, or at the company’s website (https://www.actharpulmonology.com). It is telling that in 2012, before Mallinckrodt began heavily marketing the drug, at least one-half of the most frequent prescribers of Acthar were promotional speakers or had other relationships with Questcor Pharmaceuticals, the manufacturer at the time.